$11.92 0.3%
Price vs. AI Score (Last 150 days)
Data gathered: April 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

Data Bits

Data Bits Value / Change Benchmark
Job Posts 73 4.3%
Sentiment 98 0%
Webpage traffic 59,000 -61.2%
Employee Rating 63 0%
Google Trends 8 0%
Patents 191 0%
4chan Mentions 0% N/A
Reddit Mentions 0%
Stocktwits Mentions 69 200%
Stocktwits Subscribers 10,884 0%
Twitter Followers 1,199 0.1%
Twitter Mentions 54 315.4%
News Mentions 0%
Customer reviews 0%
Business outlook 70 0%
Linkedin Employees 569 N/A

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

Iovance Biotherapeutics
Price $11.92
Target Price Sign up
Volume 5,390,000
Market Cap $3.41B
Dividend Yield 0%
Revenue per Employee $2,934
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q4 '23590,0004.4M-3.8M-116M-117M-0.450
Q3 '23470,0004.3M-3.9M-114M-114M-0.460
Q2 '23240,0002.1M-1.8M-107M-108M-0.470
Q1 '23180,0000-28M-107M-111M-0.500
Q4 '22026M-27M-105M-107M-0.640

Insider Transactions View All

Dukes Iain D. filed to buy 54,000 shares at $9.2.
February 20 '24
MCPEAK MERRILL A filed to buy 320,150 shares at $9.2.
February 20 '24
Rothbaum Wayne P. filed to buy 28,067,333 shares at $9.2.
February 20 '24
MCPEAK MERRILL A filed to buy 248,633 shares at $5.6.
September 19 '23
Rothbaum Wayne P. filed to buy 23,067,333 shares at $5.3.
September 15 '23

What is the Market Cap of Iovance Biotherapeutics?

The Market Cap of Iovance Biotherapeutics is $3.41B.

How Many People Work at Iovance Biotherapeutics?

As of our latest update, Iovance Biotherapeutics employed approximately 503 people worldwide. However, it's important to note that Iovance Biotherapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Iovance Biotherapeutics' revenue per employee?

$2,934. To calculate Iovance Biotherapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current price of Iovance Biotherapeutics?

Currently, the price of one share of Iovance Biotherapeutics is $11.92.

How can I analyze the IOVA stock price chart for investment decisions?

The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.

Does IOVA offer dividends to its shareholders?

As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Iovance Biotherapeutics?

Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.